NCT00922584已完成2 期
A Phase II Study of Sorafenib (BAY 43-9006®) in Patients With Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)Treatment
Chinese Society of Lung Cancer1 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2008年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- Disease control rate (CR+PR+SD)
研究概览
简要总结
This trial's aim is to evaluate the efficacy and toxicity of sorafenib in relapsed advanced Non-Small Cell Lung Cancer (NSCLC) after failure of epidermal growth factor receptors-tyrosine kinase inhibitor (EGFR-TKI) treatment and to explore the correlation between clinical outcomes and biochemical modulation of signal transduction pathways.
详细描述
Sorafenib, an oral multi-kinase inhibitor, targets the Raf/MEK/ERK pathway at the level of Raf kinase and VEGF receptor tyrosine kinases, and has shown efficacy against NSCLC in Phase I/II trials. Because the targets of sorafenib are different from that of EGFR-TKI, it is reasonable for sorafenib to treat relapsed advanced NSCLC after failure of EGFR-TKI treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological documented stage IIIB (not amenable for radical regional therapy) or stage IV NSCLC. The pathological diagnosis must be adenocarcinoma with or without bronchioalveolar carcinoma. Sputum cytology alone is excluded.
- •Recurrent or progressive disease after prior one EGFR-TKI treatment. The patient must have stopped the EGFR-TKI treatment for at least two weeks. The response to EGFR-TKI should be partial response or complete response or stable disease (the duration of stable disease should be more than 3 months). Patients who had never received chemotherapy or received one regimen chemotherapy before EGFR-TKI are eligible.
- •Prior surgery, including palliative surgery, is permitted if performed 4 weeks before the start of study treatment and the patient is fully recovered.
- •Prior localized radiotherapy 4 weeks before the start of study is permitted if it was not administered to target lesions selected for this study, unless progression of the selected target lesions within the radiation portal is documented. Patient has recovered from CTCAE grade 3/4 toxicity of radiotherapy. Palliative radiotherapy within 4 weeks of start of study is also permitted.
- •Age > 18 years.
- •ECOG Performance Status of 0, 1,or
- •Life expectancy of at least 3 months. Measurable disease, according to the RECIST, the presence of at least one uni-dimensional measurable lesion with longest diameter > 20 mm by conventional techniques or > 10 mm by spiral CT scan.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •Hemoglobin > 9.0 g/dl
- •Platelet count > 75x109/L
- •Total bilirubin ≤ 1.5 x upper limit of normal
- •ALT and AST < 2.5 x upper limit of normal without liver metastasis, ALT and AST < 5 x upper limit of normal with liver metastasis.
- •International normalized ratio (INR) ≤ 1.5 x the upper limit of normal and prothrombin time (PT) ≤ 1.5 x the upper limit of normal. Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.
- •Serum creatinine < 1.5 x upper limit of normal.
排除标准
- •Patients who are currently enrolled in, are eligible for, or have access to, any other sorafenib clinical trial.
- •Mixed small cell and non-small cell lung cancer histology. Other pathological types of NSCLC than adenocarcinoma and bronchioloalveolar cell carcinoma.
- •Failure of EGFR-TKI is due to toxicity.
- •Prior with exposure to biotherapy, immunotherapy within 4 weeks of study entry.
- •Prior exposure to sorafenib or other agents targeting the Ras/MARK pathway or VEGFR.
- •Any unresolved toxicity more than CTCAE grade 2 from previous anti-cancer therapy.
- •Patients with cardiac arrhythmias greater than grade 1 NCI CTCAE, Version 3.0(Conduction abnormality and supraventricular arrhythmia present but patient is asymptomatic; intervention not indicated, palpitations present and QTC > 0.45-0.47 second); however, patients with grade 2 atrial fibrillation may be included.
- •Significant cardiovascular event: congestive heart failure > NYHA class 2; unstable angina, active CAD (myocardial infarction more than 6 months prior to study entry is allowed); serious cardiac arrhythmia requiring anti-arrythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
- •Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any study medication (sorafenib) or that might affect the interpretation of the results or render the subject at high risk from treatment.
- •Central nervous system (CNS) tumor or metastatic tumor.
- •Clinically significant gastrointestinal bleeding within 30 days of study entry.
研究组 & 干预措施
sorafenib
Experimental
Patients with stage IIIB/IV NSCLC who failed EGFR-TKI therapy will receive oral sorafenib 400 mg twice daily until disease progression or unacceptable toxicity.
干预措施: sorafenib (Nexavar) (Drug)
结局指标
主要结局
Disease control rate (CR+PR+SD)
时间窗: 1 year
次要结局
- Response duration(2 years)
- time-to-progression(2 years)
- progression free survival(2 years)
- overall survival(2 years)
- safety profile(2 years)
研究者
Yi-Long Wu
Director of Chinese Society of Lung Cancer/Chief of Lung Cancer Research Institute & Cancer Center/Vice President of Guangdong General hospital
Chinese Society of Lung Cancer
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaRefractory Multiple MyelomaNCT00253578National Cancer Institute (NCI)40
已完成
2 期
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaAdenocarcinoma of the Extrahepatic Bile DuctAdenocarcinoma of the GallbladderAdenocarcinoma With Squamous Metaplasia of the GallbladderCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerSquamous Cell Carcinoma of the GallbladderUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT00238212National Cancer Institute (NCI)50
已完成
2 期
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung CancerExtensive Stage Small Cell Lung CancerRecurrent Small Cell Lung CancerNCT00182689National Cancer Institute (NCI)89
进行中（未招募）
1 期
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159
已完成
2 期
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaAnaplastic Large Cell LymphomaNCT00131937National Cancer Institute (NCI)14